Archive: 2012 International Cancer Cluster Showcase

June 17, 2012, 1pm-6:30pm
Whitehead Institute
Nine Cambridge Center
Cambridge, MA 02142

Conference Description

This focused partnering event will showcases cutting edge cancer R&D activities in 5 regions and clusters: Massachusetts, Quebec, Toulouse, Oslo, and the UK “golden triangle” teamed up to present their innovative oncology pipelines to an international audience as a satellite event to BIO 2012.  The compact event features company and poster presentations and focused networking opportunities with an international oncology community.

Agenda

1:00 – 1:30  p.m.:  Registration
1:30 – 1:45  p.m.:  Opening and Welcome
1:45 – 2:15  p.m.:  CQVB Quebec, Canada
2:15 – 2:45  p.m.:  Oslo Cancer Cluster; Norway
2:45 – 3:15  p.m.:  Cancer Research UK and CRT, United Kingdom
3:15 – 3:45 p.m.:   Networking Break
3:45 – 4:15 p.m.:   Cancer-Bio-Santé Cluster and its French cluster partners, France
4:15 – 4:45  p.m.:  Massachusetts Technology Transfer Center, USA
4:45 – 5:00  p.m.:  Closing Remarks
5:00 – 6:30  p.m.:  Networking Reception & Poster Session

Presentations

All presenting companies profiles

Epitarget (Oslo)

Lytix Biopharma (Oslo)

Targovax (Oslo)

Vaccibody (Oslo)

Sanofi

Angiochem

Cancer Research Technology UK

CRT Discovery UK

Acublate UK

Senectus Therapeutics UK

Organizers

Massachusetts’ unique ecosystem of leading research institutions, supporting organizations, and investor community spurs the creation of numerous new companies every year. Massachusetts’ cancer expertise is maintained by cutting edge research at multiple institutions including the Dana-Farber Cancer Institute and the David Koch Institute for Integrative Cancer Research at MIT. Many of the newly formed companies in the Commonwealth focus on cancer diagnostics and treatment.

The Massachusetts Technology Transfer Center is a non-profit organization that supports technology transfer activities from public and private research institutions to companies in Massachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.

The CQVB (Centre québécois de valorisation des biotechnologies) is a unique organisation, which stimulates and supports technology transfer and innovation within small to medium-sized bio-industry companies in Québec Province.  The CQVB explores new opportunities for partnerships and promotes Québec’s innovative assets and technologies. Québec’s cancer expertise include 5 major universities, 7 affiliated research institutes, one dedicated network (135 researchers) and more than 20 companies involved in cancer research and product development from new targets and molecules to novel diagnostics and therapies.

Cancer-Bio-Sante Cluster: A unique and broad approach throughout the continuum of cancer. Cancer-Bio-Santé Cluster, located in Toulouse, is the French cluster in France fully dedicated to the fight against Cancer, throughout a broad continuum approach involving prevention, diagnostics, therapeutics and patient monitoring. CBS supports companies from the Midi Pyrénées and Limousin regions, which develop innovative products in the fields of food & Health, Diagnostics, Biomarkers, Nanotechnologies, Medical Devices, Immunotherapy, Therapeutics, Biotechnologies and Telemedicine.
The mission of the Cancer-Bio-Santé cluster is to support companies to develop innovative products by synergizing public and private research and clinical research actors.

Oslo Cancer Cluster: business development through cluster collaboration. Oslo Cancer Cluster is a research and industry cluster focused on oncology. The cluster is a non-profit member organization dedicated to accelerating the development of new cancer diagnostics and medicines. The 70 members represent the entire R&D value chain and include academic research institutes, university hospitals, innovative SMEs and international Pharma companies. The cluster’s strong pipeline comprises innovative cancer therapeutics and diagnostics including late stage clinical development candidates and a number of early stage projects entering clinical development in 2012.

Cancer Research UK is the world’s leading charity dedicated to saving lives through research.  The charity’s groundbreaking work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. This work is funded entirely by the public.
Cancer Research UK has been at the heart of the progress that has already seen survival rates double in the last thirty years.  Cancer Research UK supports research into all aspects of cancer through the work of more than 4,800 scientists, doctors and nurses.  In addition, we run high-profile health awareness campaigns and provide clear information to help people understand more about cancer and the steps everyone can take to reduce their risk of developing the disease. We also lobby the government to make sure cancer stays at the top of the political agenda.  Together with its partners and supporters, Cancer Research UK’s vision is to beat cancer.
Cancer Research Technology, Ltd.  is the cancer-focused technology development and commercialization arm of Cancer Research UK.

Whitehead Institute – a world-renowned non-profit research institution dedicated to improving human health through basic research. By fostering a deeply collaborative culture and enabling the pursuit of wildly creative research, Whitehead provides the ideal environment for paradigm-shifting scientific achievements. For over twenty-five years, Whitehead faculty have delivered breakthroughs that have transformed our understanding of biology and accelerated the treatment of such diseases as cancer, Alzheimer’s and diabetes.

Sponsorship Information

$ 5,000 Sponsorships Available

Sponsorship benefits:

  • Special visibility towards and international oncology community / Positioning as premier partner in oncology
  • Logo recognition and company profile at event homepage
  • Logo recognition on marketing material
  • Opportunity to present / share information on oncology partnering strategy ( 5 min presentation / contact desk / information material)
  • Focused networking opportunities, opportunity to plan dedicated scouting initiatives with the clusters & regions involved

Top